You can now read 10 articles in a month for free on Read as much as you want anywhere and anytime for just 99¢.

The Boston Globe


Ariad receives nod to resume US sales of leukemia drug

Seven weeks after Ariad Pharmaceuticals Inc. was forced to halt US sales of its leukemia drug, prompting an outcry from patients and doctors, the Food and Drug Administration issued new safety measures Friday that will allow the Cambridge biotech to resume selling the medicine.

An agreement reached between the FDA and Ariad calls for a more restrictive drug label and updated information on safety risks, letting it market the powerful and expensive treatment to a narrower set of patients suffering from blood cancer. The target US market will now be only about 1,300 patients, slightly more than half the 2,500 Ariad projected before halting marketing on Nov. 1.

Loading comments...

You have reached the limit of 10 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week